Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-08-12), the Forward Annual Dividend Yield of Dr. Lal PathLabs is 1.03%.
As of today (2026-08-12), the Trailing Annual Dividend Yield of Dr. Lal PathLabs is 0.82%.
NSE:LALPATHLAB's Forward Dividend Yield % is ranked worse than 70.49% of 61
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.92
vs NSE:LALPATHLAB: 1.03
During the past 12 months, Dr. Lal PathLabs's average Dividends Per Share Growth Rate was 16.70% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 29.40% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 19.30% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Dr. Lal PathLabs was 60.50% per year. The lowest was -8.20% per year. And the median was 29.40% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Dr. Lal PathLabs (NSE:LALPATHLAB) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Dr. Lal PathLabs Forward Dividend Yield % Related Terms
NSE:LALPATHLAB vs TMO, DHR, IDXX: Forward Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs Forward Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's Forward Dividend Yield % falls into.
Dr. Lal PathLabs Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Dr. Lal PathLabs Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 5.000000
2026-07-30
2026-07-30
0000-00-00
Cash Dividend
quarterly
INR:INR 1.000000
INR 4.000000
2026-06-25
2026-06-26
0000-00-00
Cash Dividend
quarterly
INR:INR 1.000000
INR 3.500000
2026-02-05
2026-02-05
2026-02-16
Cash Dividend
quarterly
INR:INR 1.000000
INR 3.500000
2025-11-07
2025-11-07
2025-11-17
Cash Dividend
quarterly
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Dr. Lal PathLabs's Forward Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 1.03% mean?
Dr. Lal PathLabs (NSE:LALPATHLAB) has a Forward Dividend Yield % of 1.03% as of Aug. 12, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Dr. Lal PathLabs and its competitors. According to the industry distribution chart, Dr. Lal PathLabs ranks #43 out of 61 companies in the Medical Diagnostics & Research industry, placing it in the top 70.5%.
Is Dr. Lal PathLabs' Forward Dividend Yield % too high?
Dr. Lal PathLabs' current Forward Dividend Yield % is 1.03%. The Medical Diagnostics & Research industry median Forward Dividend Yield % is 1.92. Dr. Lal PathLabs' value of 1.03% is 46.4% below this industry median. Based on the distribution chart, Dr. Lal PathLabs ranks #43 out of 61 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' Forward Dividend Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dr. Lal PathLabs ranks #43 out of 61 companies for Forward Dividend Yield %. This places Dr. Lal PathLabs in the lower half of its industry. The industry median Forward Dividend Yield % is 1.92. Dr. Lal PathLabs' value of 1.03% is 46.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 1.92, based on 61 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr. Lal PathLabs's current Forward Dividend Yield % of 1.03% is 46.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Dr. Lal PathLabs and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr. Lal PathLabs's current Forward Dividend Yield % is 1.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current Forward Dividend Yield % is 1.03% and 46.4% below the Medical Diagnostics & Research industry median of 1.92. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current Forward Dividend Yield % is 1.03% as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83.
GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.
Key valuation signals for NSE:LALPATHLAB:
Forward Dividend Yield %: 1.03%
GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
Industry Position: 46.4% below the Medical Diagnostics & Research median (#43 of 61)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score
Get the complete analysis for NSE:LALPATHLAB
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
